Revolutionizing Cancer Treatment: Nexcella’s NXC-201 Proven Effective in FDA-Approved BCMA CAR-T Cells – A 2023 Haematologica Editorial Highlight
Nexcella Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug… LOS ANGELES, March 31, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”) today announced that an editorial written by Maria Sjöstrand and Michel Sadelain of Memorial Sloan Kettering Cancer Center was published 2023 in Haematologica highlighting…